Abstract
Platelet aggregation, and activation of coagulation cascade are the key events in the development of acute coronary syndromes (ACS). Patients with this syndrome are at high risk of adverse events, such as death and myocardial infarction (MI). Optimized medical treatment for the non-ST segment elevation ACSs should consist of a combined antithrombotic / anti-anginal regimen. Standard anti-thrombotic treatment is currently unfractionated heparin (UH) and aspirin, and in high-risk patients glycoprotein IIb / IIIa inhibitors. UH has been shown to reduce the risk of death or myocardial infarction in aspirin-treated patients with ACSs, but it has a number of limitations, such as need for regular monitoring and the risk of hemorrhage and thrombocytopenia. Compared to UH, the low molecular weight heparins (LMWH) possess several important theoretical advantages for the treatment of patients with ACSs, including less non-specific binding, resistance to inactivation by platelet factor-4, more reliable anticoagulation effects, and greater factor anti-Xa activity. Recently published trials strongly support the use of LMWHs in the treatment of ACSs. These agents provide an alternative to UH that is at least as effective. The available evidence favours the use of these agents in acute cardiac care. This article explores the recent clinical data on the use of LMWHs in acute cardiac care, and looks critically at the differences between traditional therapies. Recommendations regarding the use of anti-thrombotic agents in patients with ACSs are also discussed.
Keywords: acute coronary syndromes, low-molecular weight heparins, unfractionated heparin
Current Vascular Pharmacology
Title: Low-Molecular-Weight Heparins in Acute Coronary Syndromes
Volume: 1 Issue: 3
Author(s): Mehmet E. Korkmaz
Affiliation:
Keywords: acute coronary syndromes, low-molecular weight heparins, unfractionated heparin
Abstract: Platelet aggregation, and activation of coagulation cascade are the key events in the development of acute coronary syndromes (ACS). Patients with this syndrome are at high risk of adverse events, such as death and myocardial infarction (MI). Optimized medical treatment for the non-ST segment elevation ACSs should consist of a combined antithrombotic / anti-anginal regimen. Standard anti-thrombotic treatment is currently unfractionated heparin (UH) and aspirin, and in high-risk patients glycoprotein IIb / IIIa inhibitors. UH has been shown to reduce the risk of death or myocardial infarction in aspirin-treated patients with ACSs, but it has a number of limitations, such as need for regular monitoring and the risk of hemorrhage and thrombocytopenia. Compared to UH, the low molecular weight heparins (LMWH) possess several important theoretical advantages for the treatment of patients with ACSs, including less non-specific binding, resistance to inactivation by platelet factor-4, more reliable anticoagulation effects, and greater factor anti-Xa activity. Recently published trials strongly support the use of LMWHs in the treatment of ACSs. These agents provide an alternative to UH that is at least as effective. The available evidence favours the use of these agents in acute cardiac care. This article explores the recent clinical data on the use of LMWHs in acute cardiac care, and looks critically at the differences between traditional therapies. Recommendations regarding the use of anti-thrombotic agents in patients with ACSs are also discussed.
Export Options
About this article
Cite this article as:
Korkmaz E. Mehmet, Low-Molecular-Weight Heparins in Acute Coronary Syndromes, Current Vascular Pharmacology 2003; 1 (3) . https://dx.doi.org/10.2174/1570161033476574
DOI https://dx.doi.org/10.2174/1570161033476574 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ryanodine Receptor - A Novel Therapeutic Target in Heart Disease
Recent Patents on Cardiovascular Drug Discovery Protective Effect of Edaravone on Cyclophosphamide Induced Oxidative Stress and Neurotoxicity in Rats
Current Drug Safety Structure-Based Drug Design of Peptide Mimetics Containing Large P3 Moieties as Inhibitors of Factor VIIa
Letters in Drug Design & Discovery A Review of the Hypoglycemic Effects of Five Commonly Used Herbal Food Supplements
Recent Patents on Food, Nutrition & Agriculture Thymosin β4: A Multi-Faceted Tissue Repair Stimulating Protein in Heart Injury
Current Medicinal Chemistry Prorenin and the (Pro)renin Receptor in Retinal Pathology
Current Hypertension Reviews Therapeutic Applications of Mesenchymal Stem Cells: A Comprehensive Review
Current Stem Cell Research & Therapy Novel Colchicine Derivatives and their Anti-cancer Activity
Current Topics in Medicinal Chemistry Natriuretic Peptide Signaling via Guanylyl Cyclase (GC)-A: An Endogenous Protective Mechanism of the Heart
Current Cardiology Reviews Maternal Stress and Placental Vascular Function and Remodeling
Current Vascular Pharmacology SGLT-2 Inhibitors and Nephroprotection in Patients with Diabetic and Non-diabetic Chronic Kidney Disease
Current Medicinal Chemistry The Clinical Usefulness of Nuclear Medicine Techniques in the Diagnosis of Vascular Graft Infections
Current Molecular Imaging (Discontinued) Biological and In silico Studies on Synthetic Analogues of Tyrosine Betaine as Inhibitors of Neprilysin - A Drug Target for the Treatment of Heart Failure
Current Pharmaceutical Design Joint Effect of ABCA7 rs4147929 and Body Mass Index on Progression from Mild Cognitive Impairment to Alzheimer’s Disease: The Shanghai Aging Study
Current Alzheimer Research Role of Granulocyte-colony Stimulating Factor in the Protection of Cerebral Vascular Endothelium, White Matter, and Cognition
Current Neurovascular Research Electro-acupuncture Promotes Angiogenesis via Exosomal miR-210 in the Hypoxia-induced HUVECs Mediated HIF-1α/VEGF/Notch 1 Signal Pathway
Current Neurovascular Research Advances on Semisynthesis, Total Synthesis, and Structure-Activity Relationships of Honokiol and Magnolol Derivatives
Mini-Reviews in Medicinal Chemistry Glycosaminoglycan Sulodexide Inhibition of MMP-9 Gelatinase Secretion and Activity: Possible Pharmacological Role Against Collagen Degradation in Vascular Chronic Diseases
Current Vascular Pharmacology Pyridines and Imidazopyridines with Medicinal Significance
Current Topics in Medicinal Chemistry The Efficacy and Safety of Pharmacological Treatments for Post-stroke Aphasia
CNS & Neurological Disorders - Drug Targets